Physician
Hematology
Dr. Gerald L. Denardo, MD
|
|
Give Review
Gerald L. Denardo works in the field of Hematology. He studied medicine at University of California San Francisco School of Medicine. University of California San Francisco School of Medicine is a top medical university. University of California San Francisco School of Medicine is ranked 3/3 in Research/PrimaryCare. Dr. Gerald L. Denardo is also published. He has 54 publications published. The lastest publication: "Concepts, consequences, and implications of theranosis.'
Publications
- Concepts, consequences, and implications of theranosis.
- Pretherapy prediction of nephrotoxicity after peptide radionuclide receptor therapy (PRRT).
- Health care in the United States in 2009: both sides of the "counter".
- Update: Turning the heat on cancer.
- Nanomolecular HLA-DR10 antibody mimics: A potent system for molecular targeted therapy and imaging.
- Systemic radiotherapy can cure lymphoma: a paradigm for other malignancies?
- Targeted radionuclide therapy.
- Short communication: nanoparticle thermotherapy and external beam radiation therapy for human prostate cancer cells.
- Development of multivalent radioimmunonanoparticles for cancer imaging and therapy.
- The conundrum of personalized cancer management, drug development, and economics.
- Pharmacokinetic characterization in xenografted mice of a series of first-generation mimics for HLA-DR antibody, Lym-1, as carrier molecules to image and treat lymphoma.
- Effect of antilymphoma antibody, 131I-Lym-1, on peripheral blood lymphocytes in patients with non-Hodgkin's lymphoma.
- Recombinant expression of the beta-subunit of HLA-DR10 for the selection of novel lymphoma targeting molecules.
- Selecting an intervention time for intravascular enzymatic cleavage of peptide linkers to clear radioisotope from normal tissues.
- Synthesis and radiolabeling of selective high-affinity ligands designed to target non-Hodgkin's lymphoma and leukemia.
- Thermal dosimetry predictive of efficacy of 111In-ChL6 nanoparticle AMF--induced thermoablative therapy for human breast cancer in mice.
- Direct antilymphoma activity of novel, first-generation "antibody mimics" that bind HLA-DR10-positive non-Hodgkin's lymphoma cells.
- Comparison of normal tissue pharmacokinetics with 111In/90Y monoclonal antibody m170 for breast and prostate cancer.
- Editorial: "right place, wrong place": extravasation of therapeutic drug for molecular targeted radiotherapy.
- Cure of incurable lymphoma.
- Targeted radionuclide therapy for solid tumors: an overview.
- Splenic volume change and nodal tumor response in non-Hodgkin's lymphoma patients after radioimmunotherapy using radiolabeled Lym-1 antibody.
- Implantation of different malignant human cell lines in an athymic mouse does not alter success and growth rates of either xenograft.
- Direct antilymphoma effects on human lymphoma cells of monotherapy and combination therapy with CD20 and HLA-DR antibodies and 90Y-labeled HLA-DR antibodies.
- Development of tumor targeting bioprobes ((111)In-chimeric L6 monoclonal antibody nanoparticles) for alternating magnetic field cancer therapy.
- Application of high amplitude alternating magnetic fields for heat induction of nanoparticles localized in cancer.
- Enhancement of the therapeutic index: from nonmyeloablative and myeloablative toward pretargeted radioimmunotherapy for metastatic prostate cancer.
- High-dose radioimmunotherapy combined with fixed, low-dose paclitaxel in metastatic prostate and breast cancer by using a MUC-1 monoclonal antibody, m170, linked to in...
- Treatment of non-Hodgkin's lymphoma (NHL) with radiolabeled antibodies (mAbs).
- Planning time for peripheral blood stem cell infusion after high-dose targeted radionuclide therapy using dosimetry.
- Concepts in radioimmunotherapy and immunotherapy: Radioimmunotherapy from a Lym-1 perspective.
- Characterization of site-specific ScFv PEGylation for tumor-targeting pharmaceuticals.
- New directions in radioimmunotherapy of non-Hodgkin's lymphoma.
- Radiometals as payloads for radioimmunotherapy for lymphoma.
- Evaluation of a cathepsin-cleavable peptide linked radioimmunoconjugate of a panadenocarcinoma MAb, m170, in mice and patients.
- Production of soluble ScFvs with C-terminal-free thiol for site-specific conjugation or stable dimeric ScFvs on demand.
- Radioimmunotherapy: a novel treatment modality for B-cell non-Hodgkin's lymphoma.
- Selection and characterization of anti-MUC-1 scFvs intended for targeted therapy.
- Effect of molecular size of pegylated peptide on the pharmacokinetics and tumor targeting in lymphoma-bearing mice.
- Preclinical evaluation of cathepsin-degradable peptide linkers for radioimmunoconjugates.
- Enhanced therapeutic index of radioimmunotherapy (RIT) in prostate cancer patients: comparison of radiation dosimetry for 1,4,7,10-tetraazacyclododecane-N,N',N",N...
- Documentation of idiotypic cascade after Lym-1 radioimmunotherapy in a patient with non-Hodgkin's lymphoma: basis for extended survival?
- Characterization of human IgG antimouse antibody in patients with B-cell malignancies.
- Impact of nodal regression on radiation dose for lymphoma patients after radioimmunotherapy.
- Anti-CD22 ligand-blocking antibody HB22.7 has independent lymphomacidal properties and augments the efficacy of 90Y-DOTA-peptide-Lym-1 in lymphoma xenografts.
- Application of MINERVA Monte Carlo simulations to targeted radionuclide therapy.
- Year 2002: the best year yet for CB&R.
- Cilengitide targeting of alpha(v)beta(3) integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts.
- Treatment planning for molecular targeted radionuclide therapy.
- Combined modality radioimmunotherapy. Promise and peril.
- Rationales, evidence, and design considerations for fractionated radioimmunotherapy.
- Radiation dosimetry for radionuclide therapy in a nonmyeloablative strategy.
- Combined modality radioimmunotherapy for human prostate cancer xenografts with taxanes and 90yttrium-DOTA-peptide-ChL6.
Schools
University of California At San Francisco
Letterman Army Med Center
Wm Beaumont Amc
Doctors Specialties
- Internal Medicine
- Nuclear Medicine
- Hematology
Accepted Insurances
Education
-
William Beaumont Army Medical Center -
University of California San Francisco School of Medicine
Helpful Reviews
Similar Doctors
|
|
Dr. Minh T. Huynh, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. William R. Kimball, MD |
|
|
Dr. Kit W. Tam, MD |
|
|
Dr. Kandeel K. Judge, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Tse-Lin Hsii, MD |
|
|
Dr. Carol M. Richman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jeanna L. Welborn, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Helen K. Chew, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David R. Gandara, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Vincent Caggiano, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Steven R. Ferronato, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Brian A. Jonas, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lawrence Schlachter, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robert T. O'Donnell, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Benjamin K. Tomlinson, MD |
|
|
Srinivas C. Gummaraju, MB |